Skip to main content
Log in

Evaluation of safety of endoscopic biopsy without cessation of antithrombotic agents in Japan

  • Original Article—Alimentary Tract
  • Published:
Journal of Gastroenterology Aims and scope Submit manuscript

Abstract

Background

Although guidelines in Japan recommend the cessation of antithrombotic agents before endoscopic biopsy, the safety of biopsy without the cessation of these agents has not been evaluated to date in this country. Therefore, we aimed to assess the feasibility of biopsy without cessation of antithrombotic agents in Japan.

Methods

This was a prospective single-arm study from a single institution. From May 2010 to November 2011, 112 outpatients who were receiving antithrombotic agents because of their high-risk status for a thromboembolic event (after implantation of coronary stent, after valve replacement, or a previous history of thromboembolic event or heart failure due to atrial fibrillation) were enrolled. We evaluated the rate of severe bleeding complications within 2 weeks after endoscopy and the endoscopic bleeding time (EBT) after biopsy in patients who underwent biopsy for endoscopic findings requiring pathology assessment.

Results

Among the 112 participants, 101 biopsies were performed for 48 and 12 outpatients who had had esophagogastroduodenoscopy and colonoscopy, respectively. All the biopsies provided enough specimens to evaluate pathologically. Hemostasis after biopsy was confirmed for all biopsies during endoscopic observation. No patients complained of any bleeding symptoms in the 2-week observation period after biopsy (0/101; 95% confidence interval [CI] 0–3.6%). Concerning the EBT (median 2.2 ± 1.8 min, range 0.5–9 min), there were no significant differences between patients receiving single antithrombotic agents and those receiving multiple agents (2.4 ± 1.4 vs. 2.1 ± 2.1 min), nor were there any significant differences between patients not receiving and receiving warfarin (2.3 ± 1.8 vs. 2.2 ± 1.8 min).

Conclusion

Biopsy without cessation of antithrombotic agents, as recommended in Western guidelines, can also be acceptable for Japanese people if performed carefully.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Kodashima S, Fujishiro M. Novel image-enhanced endoscopy with i-scan technology. World J Gastroenterol. 2010;16:1043–9.

    Article  PubMed  Google Scholar 

  2. Yoshida T, Inoue H, Usui S, Satodate H, Fukami N, Kudo SE. Narrow-band imaging system with magnifying endoscopy for superficial esophageal lesions. Gastrointest Endosc. 2004;59:288–95.

    Article  PubMed  Google Scholar 

  3. Collaborative overview of randomised trials of antiplatelet therapy-I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists’ Collaboration. BMJ. 1994;308:81–106.

    Google Scholar 

  4. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci. 1996;143:1–13.

    Article  PubMed  CAS  Google Scholar 

  5. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494–502.

    Article  PubMed  CAS  Google Scholar 

  6. Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373:1849–60.

    Article  PubMed  Google Scholar 

  7. Weil J, Colin-Jones D, Langman M, Lawson D, Logan R, Murphy M, et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ. 1995;310:827–30.

    Article  PubMed  CAS  Google Scholar 

  8. Sorensen HT, Mellemkjaer L, Blot WJ, Nielsen GL, Steffensen FH, McLaughlin JK, et al. Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin. Am J Gastroenterol. 2000;95:2218–24.

    PubMed  CAS  Google Scholar 

  9. Hallas J, Dall M, Andries A, Andersen BS, Aalykke C, Hansen JM, et al. Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study. BMJ. 2006;333:726.

    Article  PubMed  Google Scholar 

  10. Aronow HD, Steinhubl SR, Brennan DM, Berger PB, Topol EJ. Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention: insights from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. Am Heart J. 2009;157:369–74.

    Article  PubMed  CAS  Google Scholar 

  11. Napoleon B, Boneu B, Maillard L, Samama CM, Schved JF, Gay G, et al. Guidelines of the French Society for Digestive Endoscopy (SFED). Endoscopy. 2006;38:632–8.

    Article  PubMed  CAS  Google Scholar 

  12. Lee SY, Tang SJ, Rockey DC, Weinstein D, Lara L, Sreenarasimhaiah J, et al. Managing anticoagulation and antiplatelet medications in GI endoscopy: a survey comparing the East and the West. Gastrointest Endosc. 2008;67:1076–81.

    Article  PubMed  Google Scholar 

  13. Veitch AM, Baglin TP, Gershlick AH, Harnden SM, Tighe R, Cairns S. Guidelines for the management of anticoagulant and antiplatelet therapy in patients undergoing endoscopic procedures. Gut. 2008;57:1322–9.

    Article  PubMed  CAS  Google Scholar 

  14. Anderson MA, Ben-Menachem T, Gan SI, Appalaneni V, Banerjee S, Cash BD, et al. Management of antithrombotic agents for endoscopic procedures. Gastrointest Endosc. 2009;70:1060–70.

    Article  PubMed  Google Scholar 

  15. Hori M, Ikeda Y, Ishimaru S, Inoue H, Uchiyama S, Ogawa H, et al. Guidelines for management of anticoagulant and antiplatelet therapy in cardiovascular disease (JCS 2009). 2009, published only online. http://wwwj-circorjp/guideline/pdf/JCS2009_hori_dpdf (Japanese).

  16. Ogoshi K, Kaneko E, Tada M, MIne T, Yoshino J, Yahagi N, et al. The management of anticoagulation and antiplatelet therapy for endoscopic procedures. Gastroenterol Endosc. 2005;47:2691–5.

    Google Scholar 

  17. Fujishiro M, Oda I, Yamamoto Y, Akiyama J, Ishii N, Kakushima N, et al. Multi-center survey regarding the management of anticoagulation and antiplatelet therapy for endoscopic procedures in Japan. J Gastroenterol Hepatol. 2009;24:214–8.

    Article  PubMed  Google Scholar 

  18. Ono S, Fujishiro M, Kanzaki H, Uedo N, Yokoi C, Akiyama J, et al. Conflicting clinical environment about the management of antithrombotic agents during the periendoscopic period in Japan. J Gastroenterol Hepatol. 2011.

  19. Li Y, Sha W, Nie Y, Wu H, She Q, Dai S, et al. Effect of intragastric pH on control of peptic ulcer bleeding. J Gastroenterol Hepatol. 2000;15:148–54.

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Satoshi Ono.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ono, S., Fujishiro, M., Kodashima, S. et al. Evaluation of safety of endoscopic biopsy without cessation of antithrombotic agents in Japan. J Gastroenterol 47, 770–774 (2012). https://doi.org/10.1007/s00535-012-0538-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00535-012-0538-7

Keywords

Navigation